Skip to content
Medical Health Aged Care

Stopping long-term opioid treatment unlikely to increase suicide risk, major study finds

National Drug and Alcohol Research Centre (NDARC), UNSW Sydney 2 mins read

People on long-term opioid treatment can be reassured that stopping these medicines is not likely to increase their risk of suicide or fatal overdose, thanks to a major new study from the National Drug and Alcohol Research Centre (NDARC) at UNSW Sydney.

The Australian-first research, based on data from 3.57 million people prescribed opioids, found no evidence of an association between opioid discontinuation and death from suicide or overdose.

With growing concerns about the limited benefits and potential risks of long-term opioid use, there is increasing interest in understanding what happens when these medicines are tapered or stopped.

The new findings are particularly important, as previous studies from the US and Canada have suggested that stopping opioid treatment may increase the risk of fatal outcomes, including suicide and overdose.

“Our study provides timely and reassuring evidence for clinicians and individuals considering stopping long-term opioid treatment,” said lead researcher, Scientia Associate Professor Natasa Gisev.

“Not only did we find no increased risk of suicide, but individuals were also half as likely to experience a fatal unintentional overdose.

“These findings represent a critical contribution to the evidence base on opioid deprescribing given the global focus on reducing opioid-related harms and rates of use without compromising patient safety or quality of life.”

As part of the study, published in PAIN, the researchers identified more than 371,000 adults in NSW who had used opioids continuously for at least six months between 2003 and 2018.

This included 523 people who had died by suicide and 671 people who died from an unintentional overdose, most of whom were men.

Compared to ongoing use, opioid discontinuation was not associated with an increased risk of suicide. This remained the case even after accounting for risk factors such as mental health conditions and substance use disorders.

The authors also found that discontinuing opioids led to a 55% lower risk of fatal unintentional overdose, with the magnitude of this effect being more pronounced over time.

“Given the high prevalence of chronic pain in the community and the continued rates of opioid prescribing– despite recent declines – this work offers valuables insights for healthcare professionals and individuals living with chronic pain,” A/Prof Gisev said.

“However, we also need further research into the non-fatal outcomes of opioid discontinuation among people with chronic pain, such as the impact on pain management, and physical and emotional wellbeing.

“Such evidence may inform the implementation of safe and effective strategies for discontinuing opioids where clinically appropriate.”

-ENDS-


Contact details:

Media contact: 0401 713 850 | [email protected]

For reference: When reporting on drugs and alcohol, we encourage consultation of the Mindframe guidelines on Communicating about alcohol and other drugs’ and ‘Communicating about suicide, and the ‘Language Matters guide published by the NSW Users and AIDS Association. 

We also encourage inclusion of the following helpline information in all reporting:

People can access free and confidential advice about alcohol and other drugs by calling the National Alcohol and Other Drug Hotline on 1800 250 015.

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

  • Medical Health Aged Care, Seniors Interest
  • 08/12/2025
  • 08:56
Monash University

Men and women may need different medications to avoid broken bones

A new international study, published in Osteoporosis International and led by Monash’s Centre for Medicine Use and Safety (CMUS), investigated the risks of a…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.